{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":16,"n_cols":5,"rows_kept":16,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[10,2,10,3],[11,2,11,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910787590403321"]
[null,null,"Titolo",null,"Advances in pulmonary neuroendocrine tumor management / / editor, Kjell Öberg"]
[null,null,"Pubbl/distr/stampa",null,"London, England : , : Future Medicine Ltd., , [2013]"]
[{"$nulls":4},"©2013"]
[null,null,"ISBN",null,"1-78084-162-0"]
[null,null,"Edizione",null,"[1st ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (101 p.)"]
[null,null,"Disciplina",null,"616.99424"]
[null,null,"Soggetti",null,"Neuroendocrine tumors - Treatment"]
[{"$nulls":4},"Lungs - Tumors - Treatment"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,"Nota di contenuto",null,"Title page; Copyright page; Contents; Foreword. Advances in pulmonary neuroendocrine tumor management; 1. Classification; 2. Molecular imaging & peptide receptor radionuclide therapy; 3. Biotherapy: somatostatin analogs and IFN-α; 4. Typical and atypical bronchial carcinoid tumors; 5. Small-cell lung cancer and large-cell neuroendocrine tumors of the lung; 6. Thymic neuroendocrine tumors; 7. Algorithm for management of bronchopulmonary neuroendocrine tumors; Index"]
[null,null,null,"Sommario/riassunto","Pulmonary neuroendocrine tumors (NETs) account for approximately one-quarter of all malignant lung cancers, the vast majority being represented by small-cell lung carcinoma. This thorough overview of this challenging field from international experts explores the various existing and emerging treatment options across the NET spectrum together with approaches to diagnosis and monitoring of disease."]